These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3294015)

  • 41. Influence of infusion systems on pharmacokinetic parameters of tobramycin in newborn infants.
    Nahata MC
    Chemotherapy; 1988; 34(5):361-6. PubMed ID: 3180903
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ceftazidime combined with mecillinam: serum bactericidal titres compared with in-vitro synergy against gram-negative bacilli.
    Van der Auwera P; Vandermies A; Lieppe S; Grenier P; Bourguignon AM; Ernst F
    J Antimicrob Chemother; 1988 Jun; 21(6):745-53. PubMed ID: 3045067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age.
    van den Anker JN; Schoemaker RC; Hop WC; van der Heijden BJ; Weber A; Sauer PJ; Neijens HJ; de Groot R
    Clin Pharmacol Ther; 1995 Dec; 58(6):650-9. PubMed ID: 8529330
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.
    Brogden RN; Pinder RM; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 12(3):166-200. PubMed ID: 789045
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia.
    Kumar A; Hay MB; Maier GA; Dyke JW
    J Antimicrob Chemother; 1992 Nov; 30(5):597-602. PubMed ID: 1283606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomised dosage study of ceftazidime with single daily tobramycin for the empirical management of febrile neutropenia in patients with hematological diseases.
    Gibson J; Johnson L; Snowdon L; Joshua D; Young G; MacLeod C; Iland H; Vincent P; Kronenberg H
    Int J Hematol; 1994 Aug; 60(2):119-27. PubMed ID: 7948961
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Continuous infusion of ceftazidime with an elastomeric infusion device.
    Couldry R; Sanborn M; Klutman NE; Strayer AH
    Am J Health Syst Pharm; 1998 Jan; 55(2):145-9. PubMed ID: 9465978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness.
    Hall WH; Gerding DN; Schierl EA
    J Infect Dis; 1977 Jun; 135(6):957-61. PubMed ID: 864291
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.
    Aronoff GR; Brier RA; Sloan RS; Brier ME
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1139-42. PubMed ID: 2203304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis.
    Rosenfeld M; Gibson R; McNamara S; Emerson J; McCoyd KS; Shell R; Borowitz D; Konstan MW; Retsch-Bogart G; Wilmott RW; Burns JL; Vicini P; Montgomery AB; Ramsey B
    J Pediatr; 2001 Oct; 139(4):572-7. PubMed ID: 11598606
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Laboratory findings of tobramycin and their relation to clinical response.
    McAllister TA; Tait SC
    J Infect Dis; 1976 Aug; 134 Suppl():S20-7. PubMed ID: 823277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intermittent bolus dosing of ceftazidime in critically ill patients.
    Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE
    J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates.
    Valitalo PA; van den Anker JN; Allegaert K; de Cock RF; de Hoog M; Simons SH; Mouton JW; Knibbe CA
    J Antimicrob Chemother; 2015 Jul; 70(7):2074-7. PubMed ID: 25766737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enzymuria in neonates during treatment with tobramycin or ceftazidime.
    Tessin I; Trollfors B; Thiringer K; Bergmark J; Hultberg B
    Pediatr Infect Dis J; 1988 Feb; 7(2):142-3. PubMed ID: 2894005
    [No Abstract]   [Full Text] [Related]  

  • 56. Intermittent administration of ceftazidime to burns patients: influence of glomerular filtration.
    Conil JM; Georges B; Fourcade O; Seguin T; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Mar; 45(3):133-42. PubMed ID: 17416108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ceftazidime, a broad spectrum cephalosporin with activity against Ps. aeruginosa.
    O'Callaghan H
    J Hyg Epidemiol Microbiol Immunol; 1986; 30(4):449-53. PubMed ID: 3100612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacokinetic studies on parenteral infusion of tobramycin in newborn and premature infants].
    Toyonaga Y; Sugita M; Kurosu Y; Hori M
    Jpn J Antibiot; 1983 Oct; 36(10):2856-68. PubMed ID: 6674521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.
    Strandvik B; Malmborg AS; Alfredson H; Ericsson A
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose regimen for vancomycin not needing serum peak levels?
    Tan WH; Brown N; Kelsall AW; McClure RJ
    Arch Dis Child Fetal Neonatal Ed; 2002 Nov; 87(3):F214-6. PubMed ID: 12390995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.